When Hope Lancaster Colquhoun was prescribed Mounjaro and instantly shed the pounds, the jab felt like a 'lifeline'. But her ...

GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of ...

Williams is not the first sportsperson to promote GLP-1 weight loss medication but she is the most high profile and easily ...

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

Eli Lilly and Company is making headlines with a staggering 170% price increase for its weight-loss drug, Mounjaro, in the UK ...

Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

Can Novo Nordisk and Eli Lilly regain their former stock market glory? A lot is riding on next year's pills ...

COMMENT: The monthly cost of a private prescription exceeding £300 from next month is worrying news for the half a million ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication.